Depression
Conditions
Interventions
depression group:None
Healthy control group:None
Sponsors
Peking University Sixth Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: MDD patient group: -Age: 18-55 years old. -Diagnostic criteria: diagnosis of major depressive disorder (MDD), meeting the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and a HAMD-17 score of >=24 was required. -Treatment: patients who had not previously received electroconvulsive therapy (ECT) and were about to receive electroconvulsive therapy (ECT). Cognitive assessment will take place on 3 occasions: within one day prior to treatment; within 2-3 days after the first treatment; and within 2-5 days after the tenth treatment. Electroconvulsive therapy electrode placement needs to be bi-Temporal (BT) (classical placement). -Cognitive ability: basic cognitive ability to cooperate in completing cognitive function assessments. The patient's cognitive function needs to be assessed using the Montreal Cognitive Assessment Scale (MoCA).The MoCA score should be between 20-25, ensuring a significant difference from healthy controls. Healthy controls: -Age: 18-55 years. -Health status: no history of mental illness or cognitive dysfunction and in good health. -Cognitive assessment: normal cognitive functioning confirmed by standardized cognitive assessment tools (e.g. MoCA), MoCA score needs to be 26 and above to ensure no significant deficits in cognitive functioning. ? A clear indicator of cognitive symptoms in patients with MDD: To ensure a clear distinction between MDD patients and healthy controls in terms of cognitive functioning, a quantitative assessment using the Montreal Cognitive Assessment Scale (MoCA) is required.The MoCA score should be at less than 26, with a specific range of scores set at 20-25, to reflect cognitive impairments in the dimensions of memory, attention, and executive functioning in patients with MDD. This criterion will be used to screen qualified patients and ensure the scientific validity and reliability of the study results.
Exclusion criteria
Exclusion criteria: - History of severe neurological disease or structural brain injury (e.g., stroke, brain tumor, severe traumatic brain injury, etc.). - Use of benzodiazepines, antiepileptic drugs during treatment, as they may raise the seizure threshold and thus reduce the efficacy of MECT. - Diagnosis of dementia or other cognitive disorders (e.g., Alzheimer's disease, Parkinson's disease, etc.). - Comorbid serious medical or other life-threatening conditions that may affect the accuracy of the study results. - Currently receiving other treatments that may affect cognitive function (e.g., other brain stimulation treatments or experimental drug therapy). - Women who are pregnant or breastfeeding. - Have a history of drug or alcohol dependence that may interfere with the results of study assessments. - Received ECT treatment within the past 3 months that may affect the baseline cognitive function assessment. - Those who refuse to sign the informed consent form. - CONTRAINDICATIONS TO ECT TREATMENT: Patients with absolute or relative contraindications to ECT are excluded from the study, including: recent myocardial infarction (less than 6 months old); severe aortic aneurysm or other cardiovascular disease that may be exacerbated during ECT; uncontrolled hypertension or cerebrovascular disease; increased intracranial pressure or uncontrolled epilepsy; and severe fractures or spinal instability.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Internal consistency confidence level;half confidence;retest reliability;exploratory factor analysis (EFA);Confirmatory Factor Analysis (CFA);Criterion Validity;Discriminant Validity;Convergent Validity;Sensitivity and Specificity; | — |
Countries
China
Contacts
Public ContactQinghua Guo
Peking University Sixth Hospital
Outcome results
None listed